According to Clovis Oncology's latest financial reports the company has โฌ50.48 Million in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2021-12-31 | โฌ0.12 B | -35.16% |
2020-12-31 | โฌ0.19 B | -26.25% |
2019-12-31 | โฌ0.26 B | -41.76% |
2018-12-31 | โฌ0.45 B | -3.23% |
2017-12-31 | โฌ0.46 B | 85.66% |
2016-12-31 | โฌ0.25 B | -47.65% |
2015-12-31 | โฌ0.48 B | 21.81% |
2014-12-31 | โฌ0.39 B | 69.57% |
2013-12-31 | โฌ0.23 B | 114.85% |
2012-12-31 | โฌ0.10 B | 0.87% |
2011-12-31 | โฌ0.10 B | 544.19% |
2010-12-31 | โฌ16.76 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() BioMarin Pharmaceutical BMRN | โฌ1.10 B | 2,081.64% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | โฌ4.66 B | 9,150.69% | ๐ฌ๐ง UK |
![]() Pfizer PFE | โฌ14.98 B | 29,591.36% | ๐บ๐ธ USA |
![]() Johnson & Johnson JNJ | โฌ33.56 B | 66,396.91% | ๐บ๐ธ USA |
![]() AbbVie ABBV | โฌ4.48 B | 8,775.17% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | โฌ2.78 B | 5,422.46% | ๐บ๐ธ USA |